Sort
261,768 grants matching “gene therapy”
Preclinical development of capsid assembly modulators for the treatment of chronic hepatitis B virus infection
$1,000,000Glen Andrew Coburn · Venatorx Pharmaceuticals, Inc. · R44 · FY2022 · AI
Triple humanized ACE2-TMPRSS-FcGRT mouse models for COVID research in the C57BU6 and BALBIc backgrounds.
$1,000,000Kurt Jarnagin · Synbal, Inc. · R44 · FY2022 · AI
Plasma miRNA predictors of adverse mechanical and electrical remodeling after MI
$1,000,000Saumya Das · Massachusetts General Hospital · UH3 · FY2016 · TR
LIVER PATHOBIOLOGY AND GENE THERAPY RESEARCH CORE CENTER
$1,000,000Yeshiva University · P30 · FY2001 · DK
Novel therapy for alcoholic liver disease-associated hepatorenal syndrome
$1,000,000Mani Subramanian · Mitopower Llc · U44 · FY2022 · AA
Comparative Approach to the Hematopoietic Stem Cell
$1,000,000Children'S Hospital Boston · U01 · FY2003 · DK
Optimization of a clinical stage nanoparticle drug delivery platform
$1,000,000Bob D. Brown · Dicerna Pharmaceuticals, Inc. · R44 · FY2016 · CA
Hemophilia Point-of-Care Monitoring Device and App
$1,000,000Eugene Yan-Ho Chan · Dna Medicine Institute · R44 · FY2025 · HL
Development of a Therapeutic SAPNANO-ESO Vaccine for Prostate Cancer
$1,000,000Yicheng Wang · Immunova Therapeutics, Llc · R44 · FY2023 · CA
Novel Targeted Nanomedicine Delivering MicroRNA-30-5p ReplacementTherapy for Multi-drug Resistant Cancer Treatment
$1,000,000Robert F Place · Mirecule, Inc. · U44 · FY2020 · CA
Preclinical development of capsid assembly modulators for the treatment of chronic hepatitis B virus infection
$1,000,000Glen Andrew Coburn · Venatorx Pharmaceuticals, Inc. · R44 · FY2023 · AI
UCSC-Buck Inst. Genome Data Analysis Center for TCGA Research Network (GDAC)
$1,000,000David H Haussler · University Of California Santa Cruz · U24 · FY2014 · CA
Developing a Small Peptide to Control Autoimmune Inflammation In Type 1 Diabetes
$1,000,000David H Wagner · Op-T-Mune, Inc. · R42 · FY2019 · AI
PredicTOR: predicting patient response to mTOR pathway inhibitors prior to treatm
$1,000,000Michael Lebowitz · 20/20 Genesystems, Inc. · R44 · FY2011 · CA
Plasma miRNA predictors of adverse mechanical and electrical remodeling after MI
$1,000,000Saumya Das · Beth Israel Deaconess Medical Center · UH3 · FY2015 · TR
Transgenic Production of CD4-IgG2 for HIV Therapy
$1,000,000Progenics Pharmaceuticals, Inc. · R44 · FY2004 · AI
Riluzole Prodrugs for Melanoma and ALS
$1,000,000Allen Bernard Reitz · Fox Chase Chemical Diversity Center, Inc · R44 · FY2019 · CA
Immunotherapy of MRSA Osteomyelitis
$1,000,000M. Javad Aman · Abvacc, Inc. · R44 · FY2023 · AI
BMX-001 as a Therapeutic Agent for Treatment of Multiple Brain Metastases.
$1,000,000David S. Silberstein · Biomimetix Jv, Llc · R44 · FY2020 · CA
Development of a novel accurate therapy for multiple sclerosis
$1,000,000Gaddiel Galarza-Munoz · Autoimmunity Biologic Solutions, Inc. · R42 · FY2022 · AI
A novel, non-antibiotic, microbiome-directed agent to prevent post-surgical infection
$1,000,000Patrick Hennessey · Covira Surgical · R42 · FY2025 · AI
Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma
$1,000,000Evan Charles Unger · Nuvox Pharma, Llc · R44 · FY2022 · CA
Next Generation Autologous TIL Cancer Therapy: Development of GMP manufacturing process
$1,000,000Richard C Duke · Trampoline Pharma, Inc. · R44 · FY2023 · CA
Affordable, quantitative, point-of-care microchip-electrophoresis for screening and treatment monitoring of sickle cell disease, thalassemias, and anemias
$1,000,000Peter Galen · Hemex Health, Inc. · R44 · FY2023 · HL
SAC-COVID: An FDA-approved Phase III clinical trial evaluating the safety and therapeutic efficacy of CD24Fc in severe COVID-19 patients
$1,000,000Pan Zheng · Oncoimmune, Inc. · R44 · FY2020 · CA